Launch of PTRA Assay using Verici Dx's technology

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, notes that Thermo Fisher Scientific, the world leader in serving science, has announced the formal launch of its One Lambda™ Pre-Transplant Risk Assessment ("PTRA") Assay via its CLIA facility in Fishers, Indiana, utilizing the pre-transplant prognostic testing technology licensed by the Company to Thermo Fisher Scientific under the terms of a global licensing and commercialisation agreement announced on 15 November 2023 (the "Agreement").1

Commenting on the milestones, Sara Barrington, CEO of Verici Dx, said:

"I am delighted to see that the PTRA Assay is being launched to the clinical community so swiftly and look forward to seeing how it can help transform patient outcomes. Together with the successful transfer of technology, this demonstrates our Company's commitment to timely and effective collaboration when executing these types of agreements."

Tina Liedtky, President, Transplant Diagnostics, Thermo Fisher Scientific said:

"We're excited to introduce this innovative new tool that may help clinicians make more informed decisions about post-transplant management by providing information about patient risk of early acute rejection based on a patient's unique gene profile prior to transplant."

• Please refer to RNS number 4652T for further information. A copy of this announcement can also be found on the company website https://verici-dx-plc.flint-platform.com/regulatory-news/62760